AI assistant
CAMBIUM BIO LIMITED — Capital/Financing Update 2017
Jan 22, 2017
64666_rns_2017-01-22_9734f4a7-eed4-4842-926e-8e3299b445d7.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [287 x 133] intentionally omitted <==
==> picture [160 x 33] intentionally omitted <==
ASX Announcement
Regeneus receives upfront payment of US$5.5m from AGC
Sydney, Australia – 23 January 2017
Regeneus Ltd (ASX: RGS), a clinical stage regenerative medicine company, today announced it has received US$5.5m from AGC as an upfront payment for the exclusive rights to manufacture Progenza under the terms of the collaboration and licence announced on 29 December 2016.
Regeneus is expected to receive a further US$11m in specific development and approval milestone payments. Regeneus will be entitled, through its 50 per cent interest in Regeneus Japan, to its share of upfront licence fees, milestone payments and royalties from sub licensing the development and commercialisation of Progenza for osteoarthritis and all other clinical indications in Japan. AGC will be responsible for funding the manufacture of Progenza for the proposed Phase 2 trial for osteoarthritis in Japan under specific conditions.
ENDS
Contact for further information:
Investors:
Sandra McIntosh Investor Relations Regeneus Ltd T: +61 2 9499 8010 E: [email protected] or go to www.regeneus.com.au
About Regeneus:
Regeneus Ltd (ASX: RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
About AGC Group:
AGC Asahi Glass (or also called AGC, Registered Company name: Asahi Glass Co., Ltd., Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, biopharmaceuticals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.3 trillion Japanese yen through businesses in about 30 countries. For more information, please visit: www.agc-group.com.
25 Bridge Street, Pymble, NSW 2073
Ph: +61 2 9499 8010 • Fax: +61 2 9499 8020 • www.regeneus.com.au • ABN 13 127 035 358